179 related articles for article (PubMed ID: 38277033)
21. In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019.
Rossolini GM; Stone G; Kantecki M; Arhin FF
J Glob Antimicrob Resist; 2022 Sep; 30():214-221. PubMed ID: 35760303
[TBL] [Abstract][Full Text] [Related]
22. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.
Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF
Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796
[TBL] [Abstract][Full Text] [Related]
24. Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy.
Kalaivani R; Kali A; Surendran R; Sujaritha T; Ganesh Babu CP
Indian J Med Microbiol; 2024; 47():100530. PubMed ID: 38246242
[TBL] [Abstract][Full Text] [Related]
25. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae.
Maraki S; Mavromanolaki VE; Moraitis P; Stafylaki D; Kasimati A; Magkafouraki E; Scoulica E
Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1755-1759. PubMed ID: 33595756
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program.
Lin LY; Debabov D; Chang W; Stone G; Riccobene T
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0198521. PubMed ID: 35225651
[No Abstract] [Full Text] [Related]
27. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
[TBL] [Abstract][Full Text] [Related]
28.
Stone G; Wise M; Utt E
Microbiol Spectr; 2024 Mar; 12(3):e0147323. PubMed ID: 38329363
[TBL] [Abstract][Full Text] [Related]
29. Ceftazidime-avibactam in the treatment of bacteremia due to carbapenem-resistant gram-negative bacteria in hematological patients: Experience in a single center.
Zhen S; Lin Q; Chen Z; Shen Y; Chen X; Pang A; Yang D; Zhang R; Ma Q; He Y; Wei J; Zhai W; Jiang E; Han M; Wang J; Feng S
J Infect Chemother; 2024 Jul; 30(7):608-615. PubMed ID: 38215820
[TBL] [Abstract][Full Text] [Related]
30. Multicenter Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam Broth Disk Elution Test.
Harris H; Tao L; Jacobs EB; Bergman Y; Adebayo A; Tekle T; Lewis S; Dahlquist A; Abbey TC; Wenzler E; Humphries R; Simner PJ
J Clin Microbiol; 2023 May; 61(5):e0164722. PubMed ID: 37070979
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018.
Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971
[TBL] [Abstract][Full Text] [Related]
32. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
Avery LM; Nicolau DP
Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946
[TBL] [Abstract][Full Text] [Related]
33. Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study.
Larcher R; Laffont-Lozes P; Roger C; Doncesco R; Groul-Viaud C; Martin A; Loubet P; Lavigne JP; Pantel A; Sotto A
Front Cell Infect Microbiol; 2022; 12():1048633. PubMed ID: 36544909
[TBL] [Abstract][Full Text] [Related]
34. Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.
Smith NM; Boissonneault KR; Chen L; Petraitis V; Petraitiene R; Tao X; Zhou J; Lang Y; Kavaliauskas P; Bulman ZP; Holden PN; Cha R; Bulitta JB; Kreiswirth BN; Walsh TJ; Tsuji BT
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0052722. PubMed ID: 35924913
[TBL] [Abstract][Full Text] [Related]
35. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
[TBL] [Abstract][Full Text] [Related]
36. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717
[TBL] [Abstract][Full Text] [Related]
37. Implementation of Chromatic Super CAZ/AVI
Bianco G; Boattini M; Comini S; Leone A; Bondi A; Zaccaria T; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1165-1171. PubMed ID: 35933457
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
Le Terrier C; Nordmann P; Poirel L
J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
[TBL] [Abstract][Full Text] [Related]
39. Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing Enterobacterales.
Mushtaq S; Vickers A; Ellaby N; Woodford N; Livermore DM
J Antimicrob Chemother; 2021 Dec; 77(1):98-111. PubMed ID: 34568905
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
